E-Qure Corp. (EQUR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
E-Qure Corp. (EQUR) trades at $0.00 with AI Score 44/100 (Grade C). E-Qure Corp. is a New York-based medical device company focused on bioelectrical signal therapy for wound treatment. Market cap: $6,909, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for EQUR: EQUR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EQUR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EQUR: the 1 perspectives are evenly split.
How is this calculated? →E-Qure Corp. (EQUR) Healthcare & Pipeline Overview
E-Qure Corp. specializes in bioelectrical signal therapy devices designed to treat hard-to-cure wounds and ulcers, leveraging proprietary technology to address significant unmet medical needs in the healthcare sector.
What Is the Investment Thesis for EQUR?
E-Qure Corp. presents a unique investment thesis centered around its proprietary bioelectrical signal therapy devices, which address a substantial market for chronic wound care, estimated to reach $20 billion by 2027. The company's focus on hard-to-cure wounds positions it well within a growing segment of the medical device industry. Key value drivers include the increasing prevalence of chronic wounds, an aging population, and the rising demand for non-invasive treatment options. E-Qure's innovative technology is a significant growth catalyst, with potential partnerships and regulatory approvals serving as additional levers for expansion. However, investors may want to evaluate risks such as market competition and the company's limited operational scale.
Based on FMP financials and quantitative analysis
EQUR Key Highlights
- Market Cap: $0.00B, indicating the company's current valuation.
- P/E Ratio: -0.01, reflecting the company's financial performance.
- Beta: 1.15, suggesting volatility relative to the market.
- Dividend Yield: None, as the company does not currently distribute dividends.
- Employee Count: 1, highlighting the company's small operational scale.
Who Are EQUR's Competitors?
EQUR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| AXGN AxoGen, Inc. | $45.08 | -1.77% | $2.40B | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EQUR's Key Strengths?
- Innovative proprietary technology for wound treatment.
- Focus on a niche market with significant unmet needs.
- Established presence in the medical device industry since 1988.
What Are EQUR's Weaknesses?
- Limited operational scale with only one employee.
- Negative P/E ratio indicating financial challenges.
- Absence of dividend payments may deter some investors.
What Could Drive EQUR Stock Higher?
- Potential partnerships with healthcare providers to enhance product adoption.
- Development and commercialization of bioelectrical signal therapy devices.
- Exploration of international markets for expansion opportunities.
What Are the Key Risks for EQUR?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles impacting product approvals.
- Intense competition from established players in the medical device sector.
- Market volatility affecting investor confidence.
What Are the Growth Opportunities for EQUR?
- Expansion into international markets: E-Qure Corp. can explore opportunities in Europe and Asia, where the chronic wound care market is expanding rapidly. The global wound care market is projected to reach $20 billion by 2027, driven by increasing healthcare access and awareness. By establishing partnerships with local distributors, E-Qure can leverage its technology to capture market share in these regions.
- Development of new product lines: E-Qure has the potential to innovate and expand its product offerings within the bioelectrical signal therapy space. By investing in research and development, the company could introduce new devices targeting different types of wounds or conditions, broadening its market reach. This could significantly enhance revenue streams and strengthen its competitive position.
- Strategic partnerships with healthcare providers: Collaborating with hospitals and clinics could facilitate the adoption of E-Qure's BST devices. By demonstrating the efficacy of its products through clinical studies and real-world applications, the company could gain credibility and drive sales. These partnerships could also lead to valuable feedback for product improvements and future innovations.
- Regulatory approvals and certifications: Securing necessary certifications and approvals from regulatory bodies can open up new sales channels for E-Qure. By ensuring compliance with medical device regulations, the company can enhance its marketability and reassure potential customers of the safety and effectiveness of its products, thus expanding its customer base.
- Increased focus on chronic disease management: With the rising prevalence of chronic diseases, there is a growing emphasis on effective wound care solutions. E-Qure's BST devices align with this trend, providing a non-invasive treatment option that can improve patient outcomes. As healthcare providers seek innovative solutions for managing chronic wounds, E-Qure is well-positioned to capitalize on this demand.
What Opportunities Does EQUR Have?
- Expansion into international markets with growing demand.
- Development of new product lines to capture additional market share.
- Strategic partnerships with healthcare providers for product adoption.
What Threats Does EQUR Face?
- Intense competition from established and emerging players.
- Regulatory hurdles that could delay product approvals.
- Market volatility affecting investor confidence and funding.
What Are EQUR's Competitive Advantages?
- Proprietary technology in bioelectrical signal therapy.
- Focus on hard-to-cure wounds, a niche market.
- Established brand presence since 1988.
- Potential for strategic partnerships with healthcare providers.
- Innovative approach to wound care with non-invasive solutions.
What Does EQUR Do?
E-Qure Corp., incorporated in 1988, is a medical device company headquartered in New York City, dedicated to developing and commercializing bioelectrical signal therapy (BST) devices. The company focuses on innovative solutions for treating hard-to-cure wounds and ulcers, utilizing patented electrical stimulation technologies that promote wound healing and closure. E-Qure's BST devices are designed to provide a non-invasive treatment option, offering significant advantages over traditional methods. The company's commitment to advancing wound care technology positions it uniquely within the healthcare landscape, addressing a critical need for effective treatment options. Over the years, E-Qure has evolved its product offerings and technology to enhance patient outcomes and support healthcare providers in managing complex wound care cases. With a small team of one employee, the company remains agile and focused on its mission to improve the quality of life for patients suffering from chronic wounds.
What Products and Services Does EQUR Offer?
- Develop bioelectrical signal therapy devices for wound treatment.
- Utilize proprietary electrical stimulation technologies.
- Focus on hard-to-cure wounds and ulcers.
- Commercialize innovative medical devices in the healthcare sector.
- Address significant unmet medical needs in wound care.
- Promote complete closure and/or cure of chronic wounds.
How Does EQUR Make Money?
- Generate revenue through the sale of bioelectrical signal therapy devices.
- Leverage patented technologies to differentiate products in the market.
- Focus on partnerships with healthcare providers for product adoption.
- Explore international market opportunities to expand customer base.
- Invest in research and development for future product innovations.
What Industry Does EQUR Operate In?
The medical devices industry is experiencing robust growth, driven by technological advancements and increasing healthcare expenditures. The wound care segment, specifically, is projected to grow significantly due to the rising incidence of diabetes and other chronic conditions leading to complex wounds. E-Qure Corp. operates in a competitive landscape, facing peers such as ABMC, ACCA, AHPIQ, CRXM, and FPSUF, each vying for market share in the innovative wound care solutions sector. The demand for effective and efficient treatment options continues to rise, providing a favorable environment for E-Qure's BST devices.
Who Are EQUR's Key Customers?
- Healthcare providers including hospitals and clinics.
- Patients suffering from chronic wounds and ulcers.
- Medical professionals seeking innovative wound care solutions.
- Insurance companies covering advanced wound treatment options.
- Distributors in the medical device market.
F-Score 1/9Financial Health
E-Qure Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 175%Key Financial Metrics
Return on equity for E-Qure Corp. stands at 175.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.17 means current liabilities exceed short-term assets, a liquidity point worth watching.
EQUR Valuation & Market Position
With a 7K market cap, E-Qure Corp. sits in the micro-cap segment of the market. Relative to its peer group, EQUR's quantitative score of 44/100 is below the peer average of 69/100.
EQUR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative proprietary technology for wound treatment.
- Focus on a niche market with significant unmet needs.
- Established presence in the medical device industry since 1988.
- Upcoming: Potential partnerships with healthcare providers to enhance product adoption.
Bear Case
- Limited operational scale with only one employee.
- Negative P/E ratio indicating financial challenges.
- Absence of dividend payments may deter some investors.
- Potential: Regulatory hurdles impacting product approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
EQUR Latest News
No recent news available for EQUR.
EQUR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EQUR.
Price Targets
Wall Street price target analysis for EQUR.
EQUR MoonshotScore
What does this score mean?
The MoonshotScore rates EQUR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ohad Goren
CEO
Ohad Goren has been leading E-Qure Corp. since its inception in 1988. With a background in medical technology and business management, he has dedicated his career to developing innovative solutions in the healthcare sector. His expertise lies in medical device commercialization and strategic growth initiatives.
Track Record: Under Ohad Goren's leadership, E-Qure has developed proprietary bioelectrical signal therapy technologies and established a presence in the medical device industry. His strategic vision has guided the company through its early years and positioned it for future growth.
EQUR OTC Market Information
The OTC Other tier represents stocks that do not meet the requirements for higher tiers like OTCQX or OTCQB. These companies typically have lower trading volumes and may not provide comprehensive financial disclosures, making them riskier for investors compared to those listed on major exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial transparency due to unknown disclosure status.
- Potential for lower liquidity and higher volatility in trading.
- Regulatory risks associated with OTC market listings.
- Verify the company's financial health and operational metrics.
- Research the competitive landscape and market positioning.
- Assess the management team's experience and track record.
- Evaluate the regulatory environment for medical devices.
- Investigate any existing partnerships or collaborations.
- Established presence in the medical device industry since 1988.
- Development of proprietary technology for wound care.
- Focus on addressing significant unmet medical needs.
E-Qure Corp. Healthcare Stock: Key Questions Answered
What does E-Qure Corp. do?
E-Qure Corp. specializes in developing bioelectrical signal therapy devices aimed at treating hard-to-cure wounds and ulcers. The company utilizes proprietary electrical stimulation technologies to promote wound healing and closure, providing innovative solutions in the medical device sector.
What do analysts say about EQUR stock?
Analysts have mixed views on EQUR stock, primarily due to its small scale and negative P/E ratio. While the proprietary technology presents potential growth opportunities, concerns regarding market competition and financial transparency are prevalent among investors.
What are the main risks for EQUR?
Key risks for E-Qure Corp. include regulatory hurdles that may delay product approvals, intense competition from other medical device companies, and market volatility that could affect investor confidence. Additionally, the company's limited operational scale poses challenges in achieving significant market penetration.
What are the key factors to evaluate for EQUR?
E-Qure Corp. (EQUR) holds an AI score of 44/100 (low). Not financial advice.
How frequently does EQUR data refresh on this page?
EQUR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EQUR's recent stock price performance?
E-Qure Corp. (EQUR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative proprietary technology for wound treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EQUR overvalued or undervalued right now?
Valuing E-Qure Corp. (EQUR) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EQUR?
Before investing in E-Qure Corp. (EQUR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial reports and disclosures are currently unknown, limiting transparency.